(SRPT) Sarepta Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8036071004

Exon-Skipping Injectables, Gene Therapy

Stock: Biotechnology
Age 28.6y
MCap 2,249m
Avg Vol 2.73M (59.8M USD)
Beta 1.489
Volatility 94.10%

EPS (Earnings per Share)

EPS (Earnings per Share) of SRPT over the last years for every Quarter: "2020-12": -2.4, "2021-03": -2.1, "2021-06": -2.3, "2021-09": -0.19, "2021-12": -1.42, "2022-03": -1.2, "2022-06": -2.65, "2022-09": -2.94, "2022-12": -1.24, "2023-03": -5.86, "2023-06": -0.27, "2023-09": -0.46, "2023-12": 0.47, "2024-03": 0.37, "2024-06": 0.07, "2024-09": 0.34, "2024-12": 1.9, "2025-03": -3.42, "2025-06": 2.02, "2025-09": -0.13, "2025-12": 0,
EPS CAGR: 6.20%
EPS Trend: 57.4%
Last SUE: 0.86
Qual. Beats: 1

Revenue

Revenue of SRPT over the last years for every Quarter: 2020-12: 145.138, 2021-03: 146.931, 2021-06: 164.089, 2021-09: 189.406, 2021-12: 201.461, 2022-03: 210.83, 2022-06: 233.487, 2022-09: 230.269, 2022-12: 258.427, 2023-03: 253.5, 2023-06: 261.238, 2023-09: 331.817, 2023-12: 396.781, 2024-03: 413.464, 2024-06: 362.931, 2024-09: 467.172, 2024-12: 658.412, 2025-03: 744.856, 2025-06: 611.091, 2025-09: 399.356, 2025-12: null,
Rev. CAGR: 20.02%
Rev. Trend: 91.1%
Last SUE: 1.85
Qual. Beats: 5

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 94.1%
Value at Risk 5%th 95.0%
Relative Tail Risk -38.62%
Reward TTM
Sharpe Ratio -1.05
Alpha -107.17
CAGR/Max DD -0.49
Character TTM
Hurst Exponent 0.429
Beta 1.489
Beta Downside 1.547
Drawdowns 3y
Max DD 92.72%
Mean DD 39.67%
Median DD 26.56%

Description: SRPT Sarepta Therapeutics January 16, 2026

Sarepta Therapeutics (NASDAQ:SRPT) is a commercial-stage biopharma focused on RNA-targeted and gene-therapy modalities for rare muscular dystrophies. Its approved portfolio includes EXONDYS-51, VYONDYS-53, AMONDYS-45 (all exon-skipping antisense oligonucleotides for Duchenne muscular dystrophy, DMD) and ELEVIDYS, an AAV-based gene therapy for ambulatory pediatric DMD patients. The pipeline adds SRP-9003, a gene-therapy candidate for limb-girdle muscular dystrophy, and multiple collaborations with Roche, Arrowhead, Dyno Therapeutics and academic partners.

Key metrics as of Q4 2024: - 2023 total revenue $1.3 bn, - net loss $210 m, - cash runway into 2026; - ELEVIDYS priced at $3.2 m per dose, reflecting the premium pricing trend in gene-therapy markets; - DMD prevalence in the U.S. (~15,000 patients) provides a limited but high-margin addressable market, while broader rare-disease gene-therapy pipelines are attracting >$30 bn of venture capital in 2023, underscoring sector capital inflows. A material risk is the durability of exon-skipping efficacy and potential competition from emerging CRISPR-based therapies.

For a deeper quantitative assessment of SRPT’s valuation dynamics, you may find the analyst tools on ValueRay worth a quick look.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-271.5m TTM) > 0 and > 6% of Revenue (6% = 144.8m TTM)
FCFTA -0.11 (>2.0%) and ΔFCFTA 2.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 74.61% (prev 121.1%; Δ -46.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.07 (>3.0%) and CFO -244.6m > Net Income -271.5m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 2.95 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (100.2m) change vs 12m ago -0.21% (target <= -2.0% for YES)
Gross Margin 76.25% (prev 85.92%; Δ -9.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 68.06% (prev 45.57%; Δ 22.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -10.58 (EBITDA TTM -180.7m / Interest Expense TTM 21.8m) >= 6 (WARN >= 3)

Altman Z'' -3.63

(A) 0.52 = (Total Current Assets 2.72b - Total Current Liabilities 921.4m) / Total Assets 3.49b
(B) -1.33 = Retained Earnings (Balance) -4.64b / Total Assets 3.49b
warn (B) unusual magnitude: -1.33 — check mapping/units
(C) -0.06 = EBIT TTM -230.4m / Avg Total Assets 3.55b
(D) -2.14 = Book Value of Equity -4.64b / Total Liabilities 2.17b
Total Rating: -3.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.23

1. Piotroski 2.0pt
2. FCF Yield -14.68%
3. FCF Margin -16.11%
4. Debt/Equity 0.95
5. Debt/Ebitda -3.53
6. ROIC - WACC (= -16.01)%
7. RoE -20.31%
8. Rev. Trend 91.11%
9. EPS Trend 57.39%

What is the price of SRPT shares?

As of January 19, 2026, the stock is trading at USD 21.13 with a total of 2,269,513 shares traded.
Over the past week, the price has changed by -0.05%, over one month by +3.88%, over three months by -8.33% and over the past year by -81.91%.

Is SRPT a buy, sell or hold?

Sarepta Therapeutics has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SRPT.
  • Strong Buy: 14
  • Buy: 8
  • Hold: 4
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the SRPT price?

Issuer Target Up/Down from current
Wallstreet Target Price 20.7 -1.8%
Analysts Target Price 20.7 -1.8%
ValueRay Target Price 21.7 2.5%

SRPT Fundamental Data Overview January 15, 2026

P/E Forward = 17.301
P/S = 0.9316
P/B = 1.7034
P/EG = 159.25
Revenue TTM = 2.41b USD
EBIT TTM = -230.4m USD
EBITDA TTM = -180.7m USD
Long Term Debt = 1.04b USD (from longTermDebt, last quarter)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 1.25b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 637.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.65b USD (2.25b + Debt 1.25b - CCE 851.0m)
Interest Coverage Ratio = -10.58 (Ebit TTM -230.4m / Interest Expense TTM 21.8m)
EV/FCF = -6.81x (Enterprise Value 2.65b / FCF TTM -388.8m)
FCF Yield = -14.68% (FCF TTM -388.8m / Enterprise Value 2.65b)
FCF Margin = -16.11% (FCF TTM -388.8m / Revenue TTM 2.41b)
Net Margin = -11.25% (Net Income TTM -271.5m / Revenue TTM 2.41b)
Gross Margin = 76.25% ((Revenue TTM 2.41b - Cost of Revenue TTM 573.2m) / Revenue TTM)
Gross Margin QoQ = 62.25% (prev 75.04%)
Tobins Q-Ratio = 0.76 (Enterprise Value 2.65b / Total Assets 3.49b)
Interest Expense / Debt = 0.61% (Interest Expense 7.57m / Debt 1.25b)
Taxrate = 9.79% (25.5m / 260.8m)
NOPAT = -207.9m (EBIT -230.4m * (1 - 9.79%)) [loss with tax shield]
Current Ratio = 2.95 (Total Current Assets 2.72b / Total Current Liabilities 921.4m)
Debt / Equity = 0.95 (Debt 1.25b / totalStockholderEquity, last quarter 1.32b)
Debt / EBITDA = -3.53 (negative EBITDA) (Net Debt 637.1m / EBITDA -180.7m)
Debt / FCF = -1.64 (negative FCF - burning cash) (Net Debt 637.1m / FCF TTM -388.8m)
Total Stockholder Equity = 1.34b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.66% (Net Income -271.5m / Total Assets 3.49b)
RoE = -20.31% (Net Income TTM -271.5m / Total Stockholder Equity 1.34b)
RoCE = -9.71% (EBIT -230.4m / Capital Employed (Equity 1.34b + L.T.Debt 1.04b))
RoIC = -8.49% (negative operating profit) (NOPAT -207.9m / Invested Capital 2.45b)
WACC = 7.52% (E(2.25b)/V(3.50b) * Re(11.40%) + D(1.25b)/V(3.50b) * Rd(0.61%) * (1-Tc(0.10)))
Discount Rate = 11.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.57%
Fair Price DCF = unknown (Cash Flow -388.8m)
EPS Correlation: 57.39 | EPS CAGR: 6.20% | SUE: 0.86 | # QB: 1
Revenue Correlation: 91.11 | Revenue CAGR: 20.02% | SUE: 1.85 | # QB: 5
EPS next Quarter (2026-03-31): EPS=0.78 | Chg30d=+0.049 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=2.76 | Chg30d=-0.137 | Revisions Net=-1 | Growth EPS=+234.7% | Growth Revenue=-25.1%

Additional Sources for SRPT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle